Menovo's subsidiary has obtained the drug registration certificate for Irbesartan and Hydrochlorothiazide tablets
Menovo's wholly-owned subsidiary Ningbo Menovo Tiankang Pharmaceutical Co., Ltd. recently obtained the drug registration certificate for Irbesartan and Hydrochlorothiazide Tablets approved by the National Medical Products Administration. This medication is used to treat primary hypertension and combines the synergistic blood pressure-lowering effects of Irbesartan and Hydrochlorothiazide
According to the announcement from Menovo (603538.SH), its wholly-owned subsidiary Ningbo Menovo Tiankang Pharmaceutical Co., Ltd. (referred to as "Menovo Tiankang") recently received the Drug Registration Certificate for Irbesartan and Hydrochlorothiazide Tablets issued by the National Medical Products Administration (referred to as "NMPA").
Indication: Used for the treatment of primary hypertension. Irbesartan and Hydrochlorothiazide is a compound consisting of the angiotensin II receptor antagonist Irbesartan and the thiazide diuretic Hydrochlorothiazide. The combination of Hydrochlorothiazide and Irbesartan can produce a synergistic antihypertensive effect within its recommended therapeutic dosage range
